EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients

Marissa Z Powell iD, Kristin C Mara iD, Radhika Bansal, Matthew A Hathcock, Arushi Khurana iD, N Nora Bennani iD, Yucai Wang iD, Jonas Paludo iD, Jose Villasboas Bisneto iD, Stephen M Ansell, Patrick B Johnston, Yi Lin und 1 weitere

Cancer Medicine · 2023-04 · 12 (8) · 9228-9235

DOI: 10.1002/cam4.5665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 08.02.2023. Verfasst von Marissa Z Powell und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Bacterial Infections. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is unknown whether serum procalcitonin (PCT) concentration monitoring can differentiate between bacterial infection or cytokine release syndrome (CRS) when chimeric antigen receptor T‐cell (CAR‐T) recipients present with a constellation of signs and symptoms that may represent both complications.

Objective

The objective of the study was to assess the utility of serum PCT concentrations as a biomarker of bacterial infection in CAR‐T recipients. Study design This single‐center, retrospective, medical record review evaluated patients prescribed CAR‐T therapy until death or 30 days after infusion. Logistic regression modeling determined the association between elevated serum PCT concentrations within 48 h of fever onset and microbiologically confirmed infection. Secondary outcomes included clinically suspected infection, CAR‐T toxicity rates, and broad‐spectrum antibiotic usage. Predictive performance of PCT was assessed by area under the receiver operating characteristic curve (AUC).

Results

The 98 included patients were a median age of 63 (IQR: 55–69) years old, 47 (48%) were male, and 87 (89%) were Caucasian. Baseline demographics and clinical characteristics were similar between patients with and without a bacterial infection. Serum PCT >0.4 ng/mL within 48 h of fever was significantly associated with a microbiologically confirmed bacterial infection (OR: 2.75 [95% CI: 1.02–7.39], p = 0.045). Median PCT values in patients with and without confirmed infections were 0.40 ng/mL (IQR: 0.26, 0.74) and 0.26 ng/mL (IQR: 0.13, 0.47), respectively. The AUC for PCT to predict bacterial infection was 0.62 (95% CI 0.48–0.76). All patients experienced CRS of some grade, with no difference in CRS severity based on elevated PCT. Broad‐spectrum antibiotics were used for a median of 45% and 23% of days in those with and without confirmed infection, respectively ( p = 0.075).

Conclusion

Elevated serum PCT concentrations above 0.4 ng/mL at time of first fever after CAR‐T infusion was significantly associated with confirmed bacterial infection. Furthermore, rigorous, prospective studies should validate our findings and evaluate serial PCT measurements to optimize antimicrobial use after CAR‐T therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenBacterial InfectionsHumansMaleMiddle AgedAgedFemaleProcalcitoninRetrospective StudiesProspective StudiesBiomarkersROC CurveAnti-Bacterial AgentsCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

T-cellantibioticsantimicrobial stewardshipchimeric antigen receptorcytokine release syndromefeverimmunotherapyinfectionprocalcitonin

Substanzen

ProcalcitoninReceptors, Chimeric AntigenBiomarkersAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Marissa Z Powell, Kristin C Mara, Arushi Khurana, N Nora Bennani, Yucai Wang, Jonas Paludo, Jose Villasboas Bisneto, Jason N Barreto

Zitieren

APA

Powell, M. Z., Mara, K. C., Bansal, R., Hathcock, M. A., Khurana, A., Bennani, N. N., Wang, Y., Paludo, J., Bisneto, J. V., Ansell, S. M., Johnston, P. B., Lin, Y., & Barreto, J. N. (2023). Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients. Cancer Medicine, 12(8), 9228-9235. https://doi.org/10.1002/cam4.5665

Vancouver

Powell MZ, Mara KC, Bansal R, Hathcock MA, Khurana A, Bennani NN, et al. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients. Cancer Medicine. 2023;12(8):9228-9235. doi:10.1002/cam4.5665

BibTeX
@article{Powell2023,
  author = {Powell, Marissa Z and Mara, Kristin C and Bansal, Radhika and Hathcock, Matthew A and Khurana, Arushi and Bennani, N Nora and Wang, Yucai and Paludo, Jonas and Bisneto, Jose Villasboas and Ansell, Stephen M and Johnston, Patrick B and Lin, Yi and Barreto, Jason N},
  title = {Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {8},
  pages = {9228--9235},
  doi = {10.1002/cam4.5665}
}
Kostenlos starten →